Thalassemia From Childhood to Adulthood: How Care Transitions Between Teams

The waiting room has changed. For sixteen years the walls had cartoon fish and a nurse who knew exactly which arm gave blood most easily. Now the chairs are gray, the magazines are about retirement, and the young man with a backpack full of transfusion records is the youngest person in the room by thirty years. He is not sick today. He is simply an adult now, and the system has noticed.

Thalassemia care from children to adults is one of the least discussed but most consequential moments in living with an inherited blood disorder. The transfusions and iron-removing medicines that kept a child well through school do not stop. What changes is who orders them, who reads the scans, and who is expected to speak up when something feels off. Increasingly, that person is the patient.

This explainer walks through what a well-run handover looks like, what each team watches for, and where the evidence is honest about its limits.

Thalassemia care from children to adults: why the handover matters

Thalassemia is an inherited condition in which the body makes less hemoglobin than it should. Hemoglobin is the protein inside red blood cells that carries oxygen, and when there is too little of it the result is anemia, a shortage of healthy red cells. Two families of genes are involved. Alpha thalassemia affects the four alpha-globin genes; beta thalassemia affects the two beta-globin genes. The more genes affected, the more severe the picture, ranging from a silent carrier state to a form that needs lifelong blood transfusions (MedlinePlus, Mayo Clinic).

For decades thalassemia was treated as a childhood disease, because the most severe forms were fatal before adulthood. That has changed. Regular transfusion, iron chelation and imaging that measures iron in the heart and liver mean that people with transfusion-dependent thalassemia now routinely reach their forties, fifties and beyond (NHS, Cleveland Clinic). A disease once managed entirely in pediatric clinics now produces adults who need adult expertise: cardiology, endocrinology, hepatology, obstetrics.

The handover matters because the pediatric model and the adult model are built differently. Pediatric teams tend to coordinate everything and involve parents in every decision. Adult teams expect the patient to know their transfusion schedule, their most recent ferritin, their chelation history and when the last heart MRI was done. If that knowledge lives only in a parent’s memory or in a chart the new team cannot access, the gap between the two rooms becomes a clinical risk, not just an emotional one.

A planned transition closes that gap. It is less a single appointment than a process spanning several years, and it is the thread running through everything that follows here.

How thalassemia treatment actually works, from transfusion to chelation

Start with the problem the treatments are solving. In severe beta thalassemia the bone marrow, the spongy tissue inside bones that manufactures blood, works overtime but produces red cells that are fragile and short-lived. The body responds by expanding the marrow, which in an untreated child can enlarge the skull and facial bones, and by asking the spleen to clear the defective cells, which enlarges the spleen. Symptoms in the most severe form typically appear within the first two years of life (Mayo Clinic).

Transfusion sidesteps the faulty factory. Donated red cells raise hemoglobin, switch off the frantic marrow signal, and let a child grow normally. For transfusion-dependent thalassemia this typically means a transfusion every few weeks, often in the range of every 2–4 weeks (Cleveland Clinic). The rhythm is set by the treating team and adjusted over time.

Transfusion creates the second problem. Each unit of blood carries iron, and the human body has no natural way to excrete iron in meaningful amounts. Over months and years iron accumulates in the liver, the heart and the hormone-producing glands. Untreated, cardiac iron is historically the leading cause of death in transfusion-dependent thalassemia (NHS, Cleveland Clinic).

Iron chelation answers that. A chelator is a medicine that binds iron so the body can pass it in urine or stool. Several chelating agents exist, given by mouth or by infusion under the skin; which one, and when it starts, is decided by the hematologist based on ferritin (a blood marker of stored iron) and MRI measurements of organ iron (Mayo Clinic). Chelation is not a short course. It continues for as long as transfusions do.

Around these two pillars sit supportive measures: folic acid to help red cell production, vaccination, monitoring of growth and puberty, and in some cases removal of an overactive spleen.

Who moves to adult thalassemia care, and who is usually asked to wait

Nearly everyone with thalassemia will eventually be cared for by an adult team, but the timing and the shape of the move vary with severity.

People with thalassemia trait, sometimes called thalassemia minor, carry one affected gene and usually have mild or no anemia (MedlinePlus). They rarely have a hematology team at all. For them, transition is mostly about carrying accurate information into adulthood: knowing they are a carrier, telling a partner before planning a family, and making sure a future primary care clinician does not mistake their small red cells for iron deficiency.

People with thalassemia intermedia or non-transfusion-dependent thalassemia sit in the middle. They may need occasional transfusions during illness or pregnancy and still accumulate iron through the gut, so they need periodic monitoring rather than a fixed transfusion calendar (Cleveland Clinic). Their transfer often happens at a natural point such as finishing high school.

For transfusion-dependent thalassemia the transfer is the most structured. Most programs aim for the move around legal adulthood, at eighteen or shortly after, with preparation beginning in the early teens. The exact age is a decision for the family and both teams, not a rule.

Who is asked to wait? Pediatric teams commonly delay transfer when a patient is mid-way through a major treatment decision such as a transplant or gene therapy evaluation, when a serious complication such as new heart iron is being actively managed, when there is a significant developmental disability that changes how self-management will work, or when the adult service simply has no capacity yet. In each case the principle is the same: transfer during stability, not during crisis (NHS).

Can thalassemia get worse with age?

The honest answer is that the gene defect does not change, but its consequences accumulate. What families experience as the disease getting worse is usually one of three things.

The first is iron. Every transfused unit adds iron, and dietary iron absorption is also increased in thalassemia because the overworked marrow signals the gut to absorb more. Iron that settles in the heart can cause heart failure and rhythm problems; iron in the liver can cause scarring and, over decades, cirrhosis; iron in the pancreas and pituitary can cause diabetes, delayed puberty and low sex hormones (Mayo Clinic, Cleveland Clinic). None of this is inevitable. It tracks with how well iron has been controlled across the years, which is why adult teams spend so much time on it.

The second is the toll of chronic anemia in people who are not regularly transfused. Non-transfusion-dependent thalassemia can look mild in childhood and then produce leg ulcers, gallstones, bone thinning, blood clots and pulmonary hypertension, which means high pressure in the lung arteries, in the third and fourth decades (Cleveland Clinic). These complications are why adult follow-up matters even for people who never had a transfusion schedule.

The third is ordinary aging layered onto a chronic condition. Bone density falls in everyone after mid-life; in thalassemia it starts from a lower baseline. Kidney function, heart function and liver health all matter more at fifty than at fifteen.

So yes, thalassemia can feel worse with age, mostly because the body has had longer to store iron and longer to feel the strain. The evidence is equally clear that consistent monitoring and treatment change that trajectory substantially (NHS).

Childhood versus adulthood: what each team watches most closely

The two teams are looking at the same disease through different windows. In childhood the questions are about growth, development and building a treatment routine that a family can sustain. In adulthood the questions are about organs, hormones, fertility and independence. The table below summarizes the shift in emphasis drawn from mainstream guidance (NHS, Mayo Clinic, Cleveland Clinic).

Focus area	Pediatric team typically emphasizes	Adult team typically emphasizes
Transfusion	Establishing the schedule, matching blood to minimize antibody formation	Maintaining the schedule around work, travel and pregnancy; managing antibodies that formed over years
Iron	Starting chelation, teaching the routine, early MRI	Organ-specific iron on MRI, adjusting chelation to heart and liver findings
Growth and bones	Height, weight, puberty timing	Bone density, fracture risk, vitamin D status
Hormones	Watching for delayed puberty	Diabetes, thyroid, low sex hormones, fertility planning
Heart	Baseline function	Rhythm problems, heart failure surveillance
Liver	Iron and viral screening	Fibrosis, cirrhosis surveillance, viral hepatitis follow-up
Infection	Vaccination, spleen status	Lifelong precautions after spleen removal, prompt fever evaluation
Decision-making	Parents lead, child is involved	Patient leads, family supports as the patient wishes

Notice that nothing disappears from the list. A good pediatric program has already done baseline heart and liver imaging. A good adult program still asks about school, mood and family. The handover is a change of weighting, not a change of subject.

One difference does deserve a specific mention. Pediatric care is often delivered in a single building where the hematologist, the dietitian, the psychologist and the transfusion nurse share a corridor. Adult care is more often distributed across departments. Knowing in advance who coordinates the whole picture is one of the most useful questions a young adult can ask.

Thalassemia transition to adult care: what the first months usually look like

A well-run transfer does not begin on the day of the first adult appointment. Most structured programs describe three phases, and the evidence base supports the sequence even where the exact ages vary (NHS).

The preparation phase, often spanning the early to mid teens, is about gradually shifting knowledge and voice. The young person starts spending part of each visit alone with the clinician, learns to state their diagnosis in one sentence, and begins to keep their own record of ferritin values and transfusion dates. Parents are still in the room for the big decisions.

The transfer phase is the actual move. Where possible it includes a joint visit with both teams, or at least a warm introduction rather than a referral letter. A written transition summary travels with the patient: genotype, transfusion history, antibodies, all chelators tried and why any were stopped, most recent heart and liver MRI, vaccination record, spleen status, hormone results and a list of every specialist involved.

The first months in adult care are typically about confirmation rather than change. The adult hematologist repeats the baseline assessments they want in their own system, meets the patient at a transfusion visit, and works out the referral pathways for cardiology, endocrinology and, when relevant, fertility services. Most people report that the transfusion routine itself feels much the same; what feels different is being asked directly what they think.

Expect a few practical wrinkles. Adult transfusion units may run on different days. The pharmacy that supplies chelation may change. Appointments may not be automatically rebooked. None of these are medical problems, but any one of them can cause a missed transfusion or a chelation gap if nobody is watching. This is the period when a named coordinator on the adult side earns their keep.

Iron overload: the quiet issue adult teams watch most closely

If one thing separates good adult thalassemia care from adequate care, it is the seriousness with which iron is measured and acted on.

Ferritin, the blood test most people know, is useful but imperfect. It rises with inflammation and infection and can be falsely reassuring in some patterns of liver disease. Guidelines therefore lean on MRI. A specific MRI technique estimates how much iron is sitting in the heart muscle and in the liver, and it does so without radiation or biopsy (NHS, Mayo Clinic). Cardiac iron is the single most important number, because heart iron can rise while ferritin looks acceptable, and heart failure from iron can develop with little warning.

The chelation medicines used to remove iron fall into a small number of classes. Some are taken by mouth, some are infused slowly under the skin over many hours. Each has a different side effect profile involving the kidneys, liver, hearing, vision or blood counts, which is why regular monitoring blood tests and periodic hearing and eye checks are part of standard care (Mayo Clinic). Which agent, how it is given and any changes are decisions for the prescribing hematologist and should never be made alone.

Adherence is the unspoken theme of adult chelation. The medicine has no immediate effect that a person can feel, the harm it prevents is years away, and the routine is tedious. Adult teams know this. If chelation has become impractical because of work shifts, side effects, travel or simply exhaustion, the useful move is to say so at the next visit rather than quietly skipping. There is usually a workable adjustment, but only if the team knows.

Iron in the liver also raises the long-term stakes for anyone who acquired hepatitis C from transfusions given before modern donor screening. Adult programs screen for this and refer for treatment where appropriate (Cleveland Clinic).

Bones, hormones and fertility: the grown-up conversations

Some of the most important adult thalassemia conversations are ones a pediatric clinic could only begin.

Iron has an unfortunate affinity for the endocrine glands, the organs that make hormones. The pituitary gland at the base of the brain is especially sensitive, and iron there can reduce the signals that drive puberty and later maintain sex hormone levels. The result, called hypogonadism, means low estrogen or testosterone. In adolescence it shows up as delayed or stalled puberty; in adulthood it contributes to low bone density, low energy, mood changes and reduced fertility (Cleveland Clinic, Mayo Clinic). Iron in the pancreas raises the risk of diabetes; iron in the thyroid can slow it down. Adult teams typically check these systems on a regular cycle.

Bones deserve their own paragraph. People with thalassemia reach adulthood with thinner bones than average because of expanded marrow, low sex hormones, low vitamin D and sometimes the chelators themselves. Osteoporosis, meaning bone weak enough to fracture easily, is common in adults with thalassemia and is one of the leading causes of chronic pain in this group (Cleveland Clinic). Bone density scanning, vitamin D and calcium assessment and safe weight-bearing exercise are standard parts of adult follow-up.

Fertility and pregnancy are possible for many people with thalassemia, including those who are transfusion dependent, but they require planning. Some will need hormonal support to conceive because of pituitary iron. Pregnancy increases transfusion needs and places extra load on the heart, so heart iron should be assessed and optimized beforehand, and some chelators are not used during pregnancy (NHS). Both partners are usually offered genetic testing so the couple understands the chance of passing on the condition. These are decisions made with an adult hematologist and an obstetric team together, ideally well before conception.

What bacteria are associated with thalassemia?

People often ask this after hearing that thalassemia raises infection risk, and the answer has two parts: iron and the spleen.

Certain bacteria thrive when iron is plentiful. The best known is Yersinia enterocolitica, a gut organism that normally struggles to compete for iron but can cause severe abdominal infection in someone whose tissues are iron-loaded, particularly during treatment with certain chelating agents. Klebsiella species and Vibrio vulnificus, a marine bacterium acquired from raw seafood or seawater exposure, are also reported more often in iron-overloaded patients in the hematology literature. This is one reason a person with thalassemia who develops fever with abdominal pain or diarrhea is asked to seek assessment rather than wait it out.

The spleen is the second part. The spleen filters blood and mounts a rapid response to encapsulated bacteria, meaning organisms with a protective outer coat. When the spleen has been removed because it was destroying red cells too quickly, that defense is gone for life. The organisms of concern are Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis, which can cause overwhelming sepsis within hours (Mayo Clinic, Cleveland Clinic). Vaccination against these bacteria before and after splenectomy, annual influenza vaccination and a low threshold for treating fever as an emergency are standard recommendations (CDC).

Transfusion itself carries a small risk of transmitting infection, but in countries with modern donor screening that risk is very low; the historical burden of hepatitis B and C came from an earlier era of blood banking (Cleveland Clinic).

The practical message for a young adult leaving pediatric care is simple. Know whether you still have your spleen, carry your vaccination record, and understand that for you a fever is a reason to call, not a reason to wait.

Foods to avoid with thalassemia minor and major: diet across the lifespan

Diet advice for thalassemia is often overstated online, so it helps to separate what applies to carriers from what applies to people with a transfusion schedule.

For thalassemia minor, or trait, the evidence supports an ordinary balanced diet. The one caution concerns iron supplements. Because the red cells in thalassemia trait are small, a routine blood count can look like iron deficiency, and people are sometimes told to take iron they do not need. Mayo Clinic advises against iron supplements unless a clinician has confirmed deficiency with proper testing (Mayo Clinic). Otherwise, no food is off limits for a carrier.

For thalassemia intermedia and major the picture shifts, because the body absorbs dietary iron more avidly and transfusions add more. Mainstream guidance suggests avoiding iron-fortified cereals and multivitamins containing iron, and being modest with the richest sources such as liver and red meat, while emphasizing that food is a minor contributor compared with transfusion iron (Mayo Clinic, Cleveland Clinic). Tea and coffee taken with meals reduce iron absorption, which is one small everyday lever. Vitamin C increases iron absorption and interacts with some chelators, so whether and when to take it is a question for the treating team, not a supplement aisle decision.

Bone health adds a second theme. Adequate calcium and vitamin D matter more in thalassemia than in the general population because of the bone thinning described earlier; many adults are checked for vitamin D and supplemented under guidance (Cleveland Clinic). Folic acid, which supports red cell production, is often recommended, again on the clinician’s advice.

What the evidence does not support is any special diet, herbal product or so-called blood-building food that improves hemoglobin in thalassemia. The hemoglobin problem is genetic, and no amount of spinach changes a gene.

Transplant, gene therapy and newer medicines: what the evidence shows

Young adults arriving in adult care are often the ones asking whether anything has changed, and it is fair to say the landscape has widened without becoming simple.

Stem cell transplant replaces the patient’s blood-making system with a donor’s. It is the longest-established approach that can end the need for transfusion, and outcomes are best in younger children with a matched sibling donor and without heavy iron loading (NHS, Mayo Clinic). The procedure carries serious risks, including graft rejection, graft-versus-host disease in which donor cells attack the recipient, infertility and death, and the balance of risk shifts as people get older and accumulate organ damage. This is precisely why a transplant discussion should not be postponed until after transfer; it belongs in the late pediatric years, with the adult team involved.

Gene therapy modifies a patient’s own stem cells so they produce functional hemoglobin, avoiding the need for a donor. Approaches of this kind are approved in some countries for some people with transfusion-dependent beta thalassemia. They still require chemotherapy to make room for the modified cells, with the associated risks, and long-term data are still being collected (NHS). Eligibility is assessed case by case by specialized centers, and the decision sits entirely with the treating team and the patient.

Medicines have also moved. An injectable class known as erythroid maturation agents helps red cells develop more fully and has been shown in trials to reduce transfusion needs in some adults with transfusion-dependent beta thalassemia. It does not remove the underlying defect and is not suitable for everyone (Cleveland Clinic).

The right framing for all of these is options, not promises. Each has documented benefits and documented harms. A good adult program will lay out both without pressure.

Thalassemia life expectancy: what the evidence says about lifespan in the United States

People search for an average lifespan figure and deserve a straight answer about why one is hard to give.

Thalassemia is rare in the United States, with the CDC noting that it affects a relatively small population and that precise national numbers are limited because there is no universal registry (CDC). That means there is no reliable single figure for average life expectancy specific to the US, and any website quoting one to the year is extrapolating.

What the evidence does show is direction. Before regular chelation existed, most children with transfusion-dependent thalassemia died in the first two decades of life, overwhelmingly from cardiac iron. With regular transfusion, effective chelation and MRI-guided monitoring of heart iron, survival into the fifth and sixth decades has become common in well-resourced health systems, and the leading causes of death have shifted from the heart toward liver disease, infection and other complications of long-term iron (NHS, Cleveland Clinic). People with thalassemia trait have a normal life expectancy (MedlinePlus). People with non-transfusion-dependent forms sit between the two, with outcomes closely tied to how well complications are monitored in adulthood.

Three things appear again and again as the determinants of a long life with severe thalassemia: uninterrupted access to safe blood, consistent chelation, and continuity of specialist follow-up. The last point is exactly why the childhood-to-adult handover carries weight. Historically, the years immediately after leaving pediatric care have been a period when appointments lapse, chelation adherence falls and complications go unnoticed. A structured transition exists to prevent that dip.

The honest summary is that lifespan with thalassemia is not fixed by the diagnosis. It is heavily shaped by care, and adulthood is where that care either continues or unravels.

What people often get wrong about thalassemia care from children to adults

Some misconceptions surface so often at first adult visits that they are worth correcting directly.

Myth: the transfer means the pediatric team thinks the patient is fine now. In reality the move is about age and appropriate expertise, not about severity. A person on a transfusion schedule needs more specialist attention in adulthood, not less, because that is when iron-related organ complications tend to surface (Cleveland Clinic).

Myth: thalassemia minor needs treatment. It does not, in nearly all cases. Carriers may have mildly small red cells and mild anemia but live normal lives without therapy (MedlinePlus). The one real action is genetic awareness before having children.

Myth: feeling well means iron is under control. Iron overload is silent until it is not. Heart iron in particular can build for years without symptoms, which is why MRI surveillance continues even when someone feels perfectly healthy (Mayo Clinic).

Myth: chelation can be paused when life gets busy without consequence. Iron keeps arriving with every transfusion; gaps in chelation are cumulative. Any change to a prescribed regimen should be a conversation with the hematologist, never a private decision.

Myth: adult teams do not want parents involved. Most adult clinics welcome family in the room if the patient wants them there. The difference is that the patient decides.

Myth: a transplant or gene therapy is something to look into later. The evidence consistently shows better transplant outcomes at younger ages and lower iron burden (NHS). That makes late adolescence the right time to ask, even if the answer is that it is not suitable.

Myth: diet can raise hemoglobin. It cannot fix a genetic defect. Nutrition matters for bones, iron balance and general health, not for the underlying anemia.

Questions to ask your care team before and after transfer

The best transitions happen when the young person walks into the adult clinic already holding the questions. These are the ones experienced patients and clinicians tend to recommend, grouped by when they are most useful.

Before transfer, to the pediatric team:

• What is my exact diagnosis, including genotype, and can I have it written in one sentence I can repeat?
• Do I still have my spleen, and is my vaccination record complete and in my hands?
• What were my most recent heart and liver MRI results, and when is the next one due?
• Which chelators have I taken, and why was any of them stopped?
• Have I ever developed antibodies to transfused blood that a new blood bank must know about?
• Has anyone discussed transplant or gene therapy eligibility with me, and should that happen before I leave?

At the first adult visits:

• Who is my single point of contact if a transfusion is missed or a prescription runs out?
• Which specialists will I see for heart, hormone, bone and liver monitoring, and how often?
• How do I reach the team urgently, including after hours, if I develop a fever?
• If I want to travel, work shifts or study away from home, how does the transfusion schedule adapt?
• What should I know about fertility and pregnancy planning, and when should that conversation start?
• How does the team handle mental health, since living with a chronic condition into adulthood has its own weight?

One more question is worth asking of oneself: who else knows how to manage this if I am unwell? A partner, a roommate or a close friend who understands that a fever is an emergency, and who knows where the transition summary is kept, is part of the care team too.

When to call your doctor

Most of thalassemia care is scheduled and predictable. A small number of situations are not, and for people with this condition they should prompt a same-day call to the hematology team or a visit to emergency care rather than waiting to see how things develop.

Fever is the first. In anyone whose spleen has been removed, or whose spleen does not work well, a temperature at or above the threshold the team has set can signal overwhelming bacterial infection that progresses over hours. Guidance is consistent that this is an emergency (Mayo Clinic, Cleveland Clinic). Fever with abdominal pain or diarrhea during chelation also needs prompt assessment because of iron-loving gut bacteria.

Heart symptoms are the second. New breathlessness, especially lying flat, swelling of the ankles, a racing or irregular heartbeat, fainting or chest pain can indicate iron affecting the heart and should be evaluated urgently (NHS).

Other red flags include:

• Sudden severe pain or swelling in one leg, or sudden breathlessness with chest pain, which can indicate a blood clot, a recognized risk particularly after spleen removal.
• Yellowing of the skin or eyes, dark urine, or pain under the right ribs, which can point to liver or gallbladder problems.
• Unusual bruising, bleeding or a sudden drop in energy between transfusions.
• New hearing or vision changes while on chelation.
• Severe back or bone pain, which in thinned bones can mean a fracture.
• Increasing thirst, frequent urination or unexplained weight loss, which can be early signs of diabetes.

Pregnancy, planned or suspected, warrants an early call as well, because transfusion needs, chelation and heart monitoring all change.

These lists are not a self-diagnosis tool. Their purpose is to lower the threshold for picking up the phone. In every case, what happens next is a decision for the treating team.

Frequently asked questions

Can thalassemia get worse with age?

The genetic defect does not change, but its effects accumulate, so thalassemia can feel worse over time. Iron from transfusions and increased gut absorption builds up in the heart, liver and hormone glands over years, and in non-transfused forms chronic anemia can lead to bone thinning, gallstones, clots and lung artery pressure in adulthood. Consistent monitoring and chelation substantially change that course, which is why adult follow-up matters.

What foods are not good for thalassemia minor?

For thalassemia minor, or trait, no food needs to be avoided and a normal balanced diet is appropriate. The main caution is iron supplements: the small red cells of trait can be mistaken for iron deficiency, so iron should only be taken if a clinician confirms a true deficiency with testing. People with transfusion-dependent forms are usually advised to limit iron-fortified products and iron-containing multivitamins, on their team’s guidance.

What is the average lifespan of someone with thalassemia in the United States?

There is no reliable single figure, because thalassemia is rare in the United States and no universal registry exists. The evidence shows a clear direction: before chelation most children with severe thalassemia died young, whereas with regular transfusion, chelation and MRI-guided iron monitoring, survival into the fifth and sixth decades is now common. Thalassemia trait carries a normal life expectancy. Continuity of specialist care is a major determinant.

What bacteria are associated with thalassemia?

Two groups matter. Iron-loving bacteria such as Yersinia enterocolitica, Klebsiella species and Vibrio vulnificus cause more severe infections in iron-overloaded people, particularly during certain chelation treatments. After spleen removal, encapsulated bacteria including Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis can cause rapid, life-threatening sepsis, which is why vaccination and urgent fever evaluation are standard.

What is the thalassemia transition to adult care, and when does it start?

It is the planned process of moving from a pediatric hematology team to an adult team, usually completed around legal adulthood. Preparation typically begins in the early teens, with the young person gradually learning to describe their condition, track their own results and speak with clinicians alone. The actual transfer ideally happens during a stable period, with a written summary and, where possible, a joint introduction.

Does my transfusion schedule change when I move to an adult team?

Usually not in any medical sense; the frequency is driven by your hemoglobin and your body’s needs, not by the clinic you attend. What can change is the practical side: transfusion days, the unit’s location, blood bank procedures and the pharmacy that supplies chelation. Confirming these details before the first adult transfusion prevents accidental gaps, and any change to the medical plan is decided by the adult hematologist.

Why does the adult team keep ordering MRI scans when I feel well?

Because iron overload is silent until it causes damage. Heart iron in particular can build for years with no symptoms and then present as heart failure or rhythm problems. MRI estimates iron in the heart and liver without radiation or biopsy and is more reliable than ferritin alone, so guidelines recommend it on a regular cycle for anyone receiving transfusions, regardless of how they feel.

Is pregnancy possible with transfusion-dependent thalassemia?

For many people, yes, with planning. Pituitary iron can reduce fertility, so some need hormonal support to conceive. Pregnancy increases transfusion needs and places extra load on the heart, so heart iron is assessed and optimized beforehand, and some chelators are not used in pregnancy. Partners are usually offered genetic testing. These decisions are made jointly with the hematology and obstetric teams, ideally well before conception.

Is it too late to ask about transplant or gene therapy as an adult?

It is not too late to ask, but the evidence shows transplant outcomes are best in younger people with a matched donor and low iron burden, and risks rise with age and organ damage. Gene therapy approaches are approved in some countries for some adults with transfusion-dependent beta thalassemia, with long-term data still being gathered. Eligibility is assessed individually by specialized centers, and the decision rests with the treating team and the patient.

What should I bring to my first adult thalassemia appointment?

A written transition summary is the single most useful item: your genotype, transfusion history and any antibodies, every chelator tried and why any stopped, your latest heart and liver MRI results, vaccination record, spleen status, hormone and bone results, and a list of all specialists involved. Bring your own list of questions too, and decide in advance whether you want a family member in the room.

References

• Thalassemia: MedlinePlus
• Thalassaemia: Treatment (NHS)
• Thalassemias (Cleveland Clinic)
• About Thalassemia (CDC)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.